Tuberculosis treatment adherence in the era of COVID-19.

IF 0.1 4区社会学 0 HUMANITIES, MULTIDISCIPLINARY

South Central Review Pub Date : 2022-10-26 DOI:10.1186/s12879-022-07787-4

Christopher K Lippincott, Allison Perry, Elizabeth Munk, Gina Maltas, Maunank Shah

{"title":"Tuberculosis treatment adherence in the era of COVID-19.","authors":"Christopher K Lippincott, Allison Perry, Elizabeth Munk, Gina Maltas, Maunank Shah","doi":"10.1186/s12879-022-07787-4","DOIUrl":null,"url":null,"abstract":"Background: In-person directly observed therapy (DOT) is commonly used for tuberculosis (TB) treatment monitoring in the US, with increasing usage of video-DOT (vDOT). We evaluated the impact of COVID-19 on TB treatment adherence, and utilization and effectiveness of vDOT.Methods: We abstracted routinely collected data on individuals treated for TB disease in Baltimore, Maryland between April 2019 and April 2021. Our primary outcomes were to assess vDOT utilization and treatment adherence, defined as the proportion of prescribed doses (7 days/week) verified by observation (in-person versus video-DOT), comparing individuals in the pre-COVID and COVID (April 2020) periods.Results: Among 52 individuals with TB disease, 24 (46%) received treatment during the COVID-19 pandemic. vDOT utilization significantly increased in the COVID period (18/24[75%]) compared to pre-COVID (12/28[43%], p = 0.02). Overall, median verified adherence was similar pre-COVID and COVID periods (65% versus 68%, respectively, p = 0.96). Adherence was significantly higher overall when using vDOT (median 86% [IQR 70-98%]) compared to DOT (median 59% [IQR 55-64%], p < 0.01); this improved adherence with vDOT was evident in both the pre-COVID (median 98% vs. 58%, p < 0.01) and COVID period (median 80% vs. 62%, p = 0.01).Conclusion: vDOT utilization increased during the COVID period and was more effective than in-person DOT at verifying ingestion of prescribed treatment.","PeriodicalId":42938,"journal":{"name":"South Central Review","volume":"24 1","pages":"800"},"PeriodicalIF":0.1000,"publicationDate":"2022-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607764/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"South Central Review","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12879-022-07787-4","RegionNum":4,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"0","JCRName":"HUMANITIES, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In-person directly observed therapy (DOT) is commonly used for tuberculosis (TB) treatment monitoring in the US, with increasing usage of video-DOT (vDOT). We evaluated the impact of COVID-19 on TB treatment adherence, and utilization and effectiveness of vDOT.

Methods: We abstracted routinely collected data on individuals treated for TB disease in Baltimore, Maryland between April 2019 and April 2021. Our primary outcomes were to assess vDOT utilization and treatment adherence, defined as the proportion of prescribed doses (7 days/week) verified by observation (in-person versus video-DOT), comparing individuals in the pre-COVID and COVID (April 2020) periods.

Results: Among 52 individuals with TB disease, 24 (46%) received treatment during the COVID-19 pandemic. vDOT utilization significantly increased in the COVID period (18/24[75%]) compared to pre-COVID (12/28[43%], p = 0.02). Overall, median verified adherence was similar pre-COVID and COVID periods (65% versus 68%, respectively, p = 0.96). Adherence was significantly higher overall when using vDOT (median 86% [IQR 70-98%]) compared to DOT (median 59% [IQR 55-64%], p < 0.01); this improved adherence with vDOT was evident in both the pre-COVID (median 98% vs. 58%, p < 0.01) and COVID period (median 80% vs. 62%, p = 0.01).

Conclusion: vDOT utilization increased during the COVID period and was more effective than in-person DOT at verifying ingestion of prescribed treatment.

查看原文本刊更多论文

在 COVID-19 时代坚持结核病治疗。

背景：在美国，面对面直接观察治疗（DOT）通常用于肺结核（TB）治疗监测，视频直接观察治疗（vDOT）的使用率也在不断提高。我们评估了 COVID-19 对结核病治疗依从性的影响以及 vDOT 的使用情况和效果：我们摘录了 2019 年 4 月至 2021 年 4 月期间在马里兰州巴尔的摩市例行收集的结核病治疗者数据。我们的主要结果是评估 vDOT 的利用率和治疗依从性，vDOT 的定义是通过观察（面对面与视频 DOT）核实的处方剂量（7 天/周）比例，比较 COVID 前和 COVID（2020 年 4 月）期间的个人：与 COVID 前（12/28[43%]，P = 0.02）相比，COVID 期间（18/24[75%]）的 vDOT 使用率显著增加。总体而言，COVID 前和 COVID 期间的中位验证依从性相似（分别为 65% 和 68%，p = 0.96）。与 DOT（中位数为 59% [IQR 55-64%]，p 结论：在 COVID 期间，vDOT 的使用率有所上升，而且在核实处方治疗的摄入方面比亲自 DOT 更有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

South Central Review HUMANITIES, MULTIDISCIPLINARY-

CiteScore

0.10

自引率

0.00%

发文量